| Name | Title | Contact Details |
|---|
WithMe Health replaces an employer`s pharmacy benefit manager (PBM) with a personalized medication guidance solution that greatly improves on and expands the scope of services available in the market today. Our modern technology and rich datasets allow consistent application of proven science to create individualized medication experiences for employees and their families that are proactive, adaptive, convenient and engaging. With an innovative, outcomes-oriented business model that aligns interests across the pharmaceutical value chain, WithMe Health optimizes health outcomes and value while substantially reducing costs for employers.
Rockwell Medical Technologies, Inc. is a Wixom, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rightway Healthcare combines cutting edge patient navigation and analytics to optimize healthcare expenditure for employers and employees
From its founding in 1777 as California`s first city, San José has been a leader driven by its spirit of innovation. Today, San José stands as the largest city in Northern California and the Capital of Silicon Valley—the world`s leading center of technology innovation. San José is the 10th largest in the U.S., and is committed to remaining a top-ranked place to do business, work, live, play and learn. San José is located in Santa Clara County at the southern edge of the San Francisco Bay, about 50 miles south of San Francisco, 390 miles north of Los Angeles. The local weather is hard to beat with moderate year-round temperatures. Residents enjoy 300 days of sunshine each year and an average annual temperature of 70 degrees. The City of San José operates under the council-manager form of government, a system that combines the policy leadership of elected officials in the form of a city council, with the managerial expertise of an appointed city manager.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.